These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 3293937)

  • 1. Pharmacokinetics of antimicrobial drugs in cystic fibrosis. Aminoglycoside antibiotics.
    Horrevorts AM; Driessen OM; Michel MF; Kerrebijn KF
    Chest; 1988 Aug; 94(2 Suppl):120S-125S. PubMed ID: 3293937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A survey of extended-interval aminoglycoside dosing practices in United States adult cystic fibrosis programs.
    Prescott WA
    Respir Care; 2014 Sep; 59(9):1353-9. PubMed ID: 24782555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of multiple courses of therapy on aminoglycoside clearance in adult patients with cystic fibrosis.
    Alghanem S; Paterson I; Touw DJ; Thomson AH
    J Antimicrob Chemother; 2013 Jun; 68(6):1338-47. PubMed ID: 23435691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis.
    Touw DJ
    Pharm World Sci; 1998 Aug; 20(4):149-60. PubMed ID: 9762727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of aminoglycoside antibiotics in patients with cystic fibrosis.
    Campbell D; Thomson AH; Stack B
    Ther Drug Monit; 1999 Jun; 21(3):281-8. PubMed ID: 10365637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use.
    Al-Aloul M; Miller H; Alapati S; Stockton PA; Ledson MJ; Walshaw MJ
    Pediatr Pulmonol; 2005 Jan; 39(1):15-20. PubMed ID: 15521084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacokinetics of antibiotics in cystic fibrosis.
    Akkerman-Nijland AM; Akkerman OW; Grasmeijer F; Hagedoorn P; Frijlink HW; Rottier BL; Koppelman GH; Touw DJ
    Expert Opin Drug Metab Toxicol; 2021 Jan; 17(1):53-68. PubMed ID: 33213220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance.
    de Groot R; Smith AL
    Clin Pharmacokinet; 1987 Oct; 13(4):228-53. PubMed ID: 3311531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimisation of antibiotic therapy in cystic fibrosis patients. Pharmacokinetic considerations.
    Lindsay CA; Bosso JA
    Clin Pharmacokinet; 1993 Jun; 24(6):496-506. PubMed ID: 8513651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of the pharmacokinetics of tobramycin administered in a single daily dose or in 3 doses in cystic fibrosis].
    Canis F; Trivier D; Vic P; Ategbo S; Turck D; Husson MO
    Pathol Biol (Paris); 1998 Jun; 46(6):449-51. PubMed ID: 9769880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides.
    Young DC; Zobell JT; Stockmann C; Waters CD; Ampofo K; Sherwin CM; Spigarelli MG
    Pediatr Pulmonol; 2013 Nov; 48(11):1047-61. PubMed ID: 24000183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibiotic use in cystic fibrosis.
    Eisenberg JD
    Curr Opin Pulm Med; 1996 Nov; 2(6):439-46. PubMed ID: 9363182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of antimicrobial drugs in cystic fibrosis. Beta-lactam antibiotics.
    Lietman PS
    Chest; 1988 Aug; 94(2 Suppl):115S-120S. PubMed ID: 3293936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacokinetics and toxicity of once-daily tobramycin therapy in children with cystic fibrosis.
    Bragonier R; Brown NM
    J Antimicrob Chemother; 1998 Jul; 42(1):103-6. PubMed ID: 9700537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aminoglycoside-Induced Nephrotoxicity in Cystic Fibrosis: A Case Presentation and Review of the Literature.
    Samaniego-Picota MD; Whelton A
    Am J Ther; 1996 Mar; 3(3):248-257. PubMed ID: 11862257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended-interval once-daily dosing of aminoglycosides in adult and pediatric patients with cystic fibrosis.
    Prescott WA; Nagel JL
    Pharmacotherapy; 2010 Jan; 30(1):95-108. PubMed ID: 20030477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions.
    Touw DJ; Vinks AA; Mouton JW; Horrevorts AM
    Clin Pharmacokinet; 1998 Dec; 35(6):437-59. PubMed ID: 9884816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Is it still possible to reduce the incidence of nephrotoxicity of aminoglycosides?].
    Beauchamp D; Labrecque G; Bergeron MG
    Pathol Biol (Paris); 1995 Nov; 43(9):779-87. PubMed ID: 8746100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis.
    Li J; Coulthard K; Milne R; Nation RL; Conway S; Peckham D; Etherington C; Turnidge J
    J Antimicrob Chemother; 2003 Dec; 52(6):987-92. PubMed ID: 14585859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum cystatin C level for better assessment of glomerular filtration rate in cystic fibrosis patients treated by amikacin.
    Halacova M; Kotaska K; Kukacka J; Vavrova V; Kuzelova M; Ticha J; Prusa R
    J Clin Pharm Ther; 2008 Aug; 33(4):409-17. PubMed ID: 18613859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.